The North Star

[The North Star @TheNorthStar5]

$KZIA New article from Sept. 25th, augments the Sept 22nd article also from @curetoday $CELC $FTH $RLAY
$IBB $XBI

[Kazia Therapeutics @KaziaTx]

Treatment resistance remains a major challenge in HR+/HER2- breast cancer, even with progress from endocrine therapies and CDK4/6 inhibitors.

In a new Q&A with @curetoday, @KaziaTx CEO Dr. John Friend discusses expanding our paxalisib trial into this population, building on preclinical findings suggesting the drug may resensitize resistant tumors to CDK4/6 inhibition.

He also addresses how paxalisib's brain-penetrant design may relate to its broader biological effects, and how biomarker research could help identify which patients are most likely to benefit.

https://t.co/Ulj8LyGTw3

#BreastCancer #Oncology #ClinicalTrials #Paxalisib

[The North Star @TheNorthStar5]

@Bullstkpicks Wow, this guy is the REAL DEAL

[The North Star @TheNorthStar5]

$KZIA

[Kazia Therapeutics @KaziaTx]

New in @curetoday: @KaziaTx is expanding our #paxalisib trial to HR+/HER2- metastatic breast cancer patients who've progressed on prior treatment.

Can we help resistant tumors respond again? CEO Dr. John Friend explains - it's about reversing the biology of resistance.

https://t.co/NkXtrSEvvR

#BreastCancer #Oncology #ClinicalTrials #CancerResearch

[The North Star @TheNorthStar5]

$KZIA @KaziaTx $CELC $RLAY $FTH $IBB $XBI @Pharmdca @Maximus_Holla

https://t.co/PaCuknsZfQ

[The North Star @TheNorthStar5]

@100BOT19039861 @AnnaFlorcia dumb

[The North Star @TheNorthStar5]

@RNAiAnalyst Where you getting hurt?

[The North Star @TheNorthStar5]

$KZIA @KaziaTx ICYMI Should be 3 sell side initiations
on Kazia - imminently- The 3 banks who placed deal 3 weeks ago at $15.50 Leerink, Guggenheim, Needham

[The North Star @TheNorthStar5]

$KZIA @KaziaTx has $5.27 per share in cash.
Be rationale here for an incredible value play. $IBB $XBI $CELC $FTH

[The North Star @TheNorthStar5]

@firstroundmock STFU moron

[The North Star @TheNorthStar5]

$KZIA @KaziaTx Research note just in from BTIG:
Kazia Therapeutics Limited (KZIA, Buy 40.00): Evaluation in Rare Epilepsies To Further Validate Pax's Broad CNS Utility $IBB $XBI

[The North Star @TheNorthStar5]

$IBB $XBI $FTH $CELC $RLAY @ConfuciusTrades

[The North Star @TheNorthStar5]

$KZIA - Interesting zoom on the @KaziaTx opportunity
https://t.co/4W4pFBLm6x

[The North Star @TheNorthStar5]

$KZIA - Interesting zoom on the @KaziaTx opportunity
https://t.co/4W4pFBLm6x

[The North Star @TheNorthStar5]

@ConfuciusTrades @finviz_com 💯

[The North Star @TheNorthStar5]

$KZIA $CELC $FTH $RLAY $IBB $XBI @Varro_Analytics

[Bull Stock Picks @Bullstkpicks]

$KZIA Nice win this morning 🔥

Partner Sovargen just dosed the first patient with paxalisib in rare, treatment-resistant epilepsies. Kazia gets $2M cash, with up to $17M more in milestones plus royalties on the table

Zero approved drugs for FCD type 2 today, so real unmet need. And Kazia doesn't spend a dime, Sovargen funds it

Same molecule, more shots on goal, all while the TNBC story keeps building

Long $KZIA, not advice

https://t.co/2MySsaH5fd

[The North Star @TheNorthStar5]

@Bullstkpicks 💯

[The North Star @TheNorthStar5]

@charlottecrrll X ray room

[The North Star @TheNorthStar5]

@Keith_McPherson Where's Tyrod?

[The North Star @TheNorthStar5]

@ShaunMorash Where's Tyrod?

[The North Star @TheNorthStar5]

@Keith_McPherson He looks like a JV QB right now

[The North Star @TheNorthStar5]

$KZIA @KaziaTx $IBB $XBI $CELC $FTH $RLAY @BioStocks @StevenACohen2 @Maximus_Holla

[TW Research Group @DanCarlson33]

@Biohazard3737 I published a piece on $KZIA recently. Would love to get your thoughts on it. https://t.co/ulCQIEpv2K

[The North Star @TheNorthStar5]

@BrettErickson28 Brett why do you post? You are Mr. Irrelevant